This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
US Set to Receive COVID-19 Vaccine Booster Dose Next Month
by Indrajit Bandyopadhyay
In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) booster dose of COVID-19 vaccine elicited antibody levels that were much higher than that seen after the two-dose primary schedule.
Company News for Aug 17, 2021
by Zacks Equity Research
Companies in The News are: NIU,SA,PFE,BNTX,TSLA
Pfizer's (PFE) Tick-Borne Encephalitis Vaccine Gets FDA Nod
by Zacks Equity Research
Pfizer's (PFE) tick-borne encephalitis vaccine that is already approved in Europe and other countries gains FDA approval.
Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccine
by Zacks Equity Research
The FDA authorizes third dose of Moderna's (MRNA) COVID-19 vaccine for use in immunocompromised adults.
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.
Stock Market News for Jul 29, 2021
by Zacks Equity Research
U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $286.26, marking a +1.53% move from the previous day.
Will Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs
by Zacks Equity Research
Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $245.17, marking a +1.04% move from the previous day.
Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
by Zacks Equity Research
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
F-star (FSTX), AstraZeneca Team Up for Novel STING Inhibitors
by Zacks Equity Research
F-star partners with AstraZeneca for its novel STING inhibitor compounds. Resultantly, F-star's shares rise 9.1%.
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
by Zacks Equity Research
BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan
by Zacks Equity Research
ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7. The filing constitutes a major amendment to the original NDA.
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.